Innovent Biologics, Inc. (1801.HK)

HKD 36.2

(-0.82%)

EBITDA Summary of Innovent Biologics, Inc.

Innovent Biologics, Inc.'s latest annual EBITDA in 2023 was -660.68 Million CNY , up 60.64% from previous year.
Innovent Biologics, Inc.'s latest quarterly EBITDA in 2024 Q2 was -124.43 Million CNY , down 0.0% from previous quarter.
Innovent Biologics, Inc. reported an annual EBITDA of -1.74 Billion CNY in 2022, up 39.67% from previous year.
Innovent Biologics, Inc. reported an annual EBITDA of -2.37 Billion CNY in 2021, down -295.92% from previous year.
Innovent Biologics, Inc. reported a quarterly EBITDA of -124.43 Million CNY for 2024 Q2, down 0.0% from previous quarter.
Innovent Biologics, Inc. reported a quarterly EBITDA of -370.87 Million CNY for 2023 Q3, down -35.7% from previous quarter.

Annual EBITDA Chart of Innovent Biologics, Inc. (2023 - 2016)

Historical Annual EBITDA of Innovent Biologics, Inc. (2023 - 2016)

Year	EBITDA	EBITDA Growth
2023	-660.68 Million CNY	60.64%
2022	-1.74 Billion CNY	39.67%
2021	-2.37 Billion CNY	-295.92%
2020	-704.73 Million CNY	53.42%
2019	-1.57 Billion CNY	72.54%
2018	-5.73 Billion CNY	-802.9%
2017	-597.72 Million CNY	-40.05%
2016	-359.91 Million CNY	0.0%

Year	EBITDA	EBITDA Growth
2024 Q1	-124.43 Million CNY	66.45%
2024 Q2	-124.43 Million CNY	0.0%
2023 Q3	-370.87 Million CNY	-35.7%
2023 Q1	-273.29 Million CNY	64.37%
2023 Q2	-273.29 Million CNY	0.0%
2023 Q4	-370.87 Million CNY	0.0%
2023 FY	- CNY	60.64%
2022 Q2	-671.86 Million CNY	0.0%
2022 Q4	-767.01 Million CNY	0.0%
2022 FY	- CNY	39.67%
2022 Q3	-767.01 Million CNY	-14.16%
2022 Q1	-671.86 Million CNY	17.78%
2021 Q4	-817.15 Million CNY	0.0%
2021 Q3	-817.15 Million CNY	-80.86%
2021 Q2	-451.82 Million CNY	0.0%
2021 Q1	-451.82 Million CNY	-476.43%
2021 FY	- CNY	-295.92%
2020 FY	- CNY	53.42%
2020 Q4	120.02 Million CNY	0.0%
2020 Q3	120.02 Million CNY	132.92%
2020 Q2	-364.63 Million CNY	0.0%
2020 Q1	-364.63 Million CNY	30.97%
2019 FY	- CNY	72.54%
2019 Q1	-344.64 Million CNY	33.56%
2019 Q3	-528.24 Million CNY	-53.27%
2019 Q4	-528.24 Million CNY	0.0%
2019 Q2	-344.64 Million CNY	0.0%
2018 Q1	-234.15 Million CNY	-34.95%
2018 Q4	-518.7 Million CNY	0.0%
2018 Q3	-518.7 Million CNY	-121.52%
2018 Q2	-234.15 Million CNY	0.0%
2018 FY	- CNY	-802.9%
2017 Q1	-108.92 Million CNY	0.0%
2017 FY	- CNY	-40.05%
2017 Q4	-173.51 Million CNY	0.0%
2017 Q3	-173.51 Million CNY	-59.3%
2017 Q2	-108.92 Million CNY	0.0%
2016 FY	- CNY	0.0%

Peer EBITDA Comparison of Innovent Biologics, Inc.

Name	EBITDA	EBITDA Difference
Uni-Bio Science Group Limited	91.23 Million HKD	824.164%
CK Life Sciences Int'l., (Holdings) Inc.	486.79 Million HKD	235.721%